Health Care • Biotechnology: Pharmaceutical Preparations
$20.01 ▼ -0.14
(-0.69%)
MKT CAP: $63.23B • VOL: 4.81M
52W L $13 52W H $21
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$17
MEDIAN
$22
MEAN
$23
HIGH
$27
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE TAK TAPE
TAK // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $24.21 | $23.01 | 2025-02-14 | $18.21 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $25.21 | $23.61 | 2025-02-06 | $18.81 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $22.81 | $22.01 | 2025-01-29 | $19.21 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $20.41 | — | 2025-01-17 | $19.61 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $17.61 | $19.01 | 2025-01-09 | $17.81 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $23.81 | $20.81 | 2024-12-18 | $17.41 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $19.41 | $20.21 | 2024-12-04 | $18.61 | -4.3% | 48% | C |